Biosimilar Patent Battle Will Have to Wait, Judge Says
SAN FRANCISCO — After a decade of work and tens of millions in spending, Sandoz fears its debut of a drug for the skin condition psoriasis will be met with a crippling patent infringement suit.
This article has been archived, and is no longer available on this website.
Not a LexisNexis® Subscriber?
For questions call 1-877-256-2472 or contact us at firstname.lastname@example.org